Harder EM - Search Results

1

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein SE, Shafman TD, Dosoretz AP, Evans SB, Husain ZA, Yu JB, Gross CP, Decker RH. Stahl JM, et al. Among authors: harder em. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1011-1020. doi: 10.1016/j.ijrobp.2016.08.033. Epub 2016 Aug 31. Int J Radiat Oncol Biol Phys. 2016. PMID: 27869080

2

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.

Park HS, Harder EM, Mancini BR, Decker RH. Park HS, et al. Among authors: harder em. J Thorac Oncol. 2015 May;10(5):832-837. doi: 10.1097/JTO.0000000000000484. J Thorac Oncol. 2015. PMID: 25634007 Free article.

3

Dose-Volume Predictors of Esophagitis After Thoracic Stereotactic Body Radiation Therapy.

Harder EM, Chen ZJ, Park HS, Mancini BR, Decker RH. Harder EM, et al. Am J Clin Oncol. 2017 Oct;40(5):477-482. doi: 10.1097/COC.0000000000000195. Am J Clin Oncol. 2017. PMID: 26017483 Clinical Trial.

4

Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.

Harder EM, Park HS, Nath SK, Mancini BR, Decker RH. Harder EM, et al. Pract Radiat Oncol. 2015 Nov-Dec;5(6):e643-9. doi: 10.1016/j.prro.2015.07.003. Epub 2015 Jul 17. Pract Radiat Oncol. 2015. PMID: 26412341

5

Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.

Harder EM, Park HS, Chen ZJ, Decker RH. Harder EM, et al. Pract Radiat Oncol. 2016 Nov-Dec;6(6):e353-e359. doi: 10.1016/j.prro.2016.01.015. Epub 2016 Feb 4. Pract Radiat Oncol. 2016. PMID: 27156424

6

Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients.

Mancini BR, Park HS, Harder EM, Rutter CE, Corso CD, Decker RH, Husain ZA. Mancini BR, et al. Among authors: harder em. Lung Cancer. 2016 Jul;97:22-7. doi: 10.1016/j.lungcan.2016.04.011. Epub 2016 Apr 19. Lung Cancer. 2016. PMID: 27237023

7

Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging.

Rahaghi FN, Nardelli P, Harder E, Singh I, Sánchez-Ferrero GV, Ross JC, San José Estépar R, Ash SY, Hunsaker AR, Maron BA, Leopold JA, Waxman AB, San José Estépar R, Washko GR. Rahaghi FN, et al. Chest. 2021 Dec;160(6):2220-2231. doi: 10.1016/j.chest.2021.06.069. Epub 2021 Jul 13. Chest. 2021. PMID: 34270966 Free PMC article.

8

Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014.

Harder EM, Small AM, Fares WH. Harder EM, et al. Respir Med. 2020 Jan;161:105850. doi: 10.1016/j.rmed.2019.105850. Epub 2019 Nov 28. Respir Med. 2020. PMID: 32056724 Free article.

9

Hospitalizations with hereditary hemorrhagic telangiectasia and pulmonary hypertension in the United States from 2000 to 2014.

Harder EM, Fares WH. Harder EM, et al. Respir Med. 2019 Feb;147:26-30. doi: 10.1016/j.rmed.2018.12.013. Epub 2019 Jan 2. Respir Med. 2019. PMID: 30704695 Free article.

10

Clinical Probability Tools for Deep Venous Thrombosis, Pulmonary Embolism, and Bleeding.

Harder EM, Desai O, Marshall PS. Harder EM, et al. Clin Chest Med. 2018 Sep;39(3):473-482. doi: 10.1016/j.ccm.2018.04.001. Clin Chest Med. 2018. PMID: 30122172 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters